Rodman & Renshaw Healthcare C

RNS Number : 6887U

Oxford Biomedica PLC

19 May 2008

 



For Immediate Release	19 MAY 2008

OXFORD BIOMEDICA TO PRESENT AT RODMAN & RENSHAW HEALTHCARE CONFERENCE

Oxford, UK - 19 May 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Nick Woolf, the Company's SVP Corporate Strategy, will present a company update on Tuesday, 20 May 2008 at 11.40 am CEST/ 10:40 am BST at the Rodman & Renshaw 5th Annual Global Healthcare Conference being held in Monte Carlo, Monaco. 

The presentation will be webcast live and may be accessed under the investors section of the Company's website, www.oxfordbiomedica.co.uk. The presentation will also be available for replay.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  Professor Alan Kingsman, Chief Executive	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Holly Griffiths/ Katja Stout/ Claire Mosley College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, a therapeutic vaccine for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. 

Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NRAGUUGCAUPRGCQ